Skip to main content
Menu

Sepsis - Monthly Reports

List of monthly reports on Sepsis

Sepsis Research Analysis

April’s sepsis research converged on host-directed mechanisms and rigorous clinical testing. Mechanistic advances included a conserved enhancer controlling B cell IL-10, a neutrophil migratory checkpoint (RPSA–OLFM4) with human validation, and two complementary NLRP3 strategies: an LRR-binding inhibitor (LOC14) that overcomes MCC950 resistance and a dual-target approach (roburic acid nanoparticles) coordinating inflammasome and redox control. Clinically, a large pragmatic NEJM trial found no kid

Sepsis Research Analysis

March 2026 sepsis research converged on deployable precision care and host-directed immunomodulation. A large phase 3 RCT showed that procalcitonin-guided ED assessment reduced 28-day mortality, while a prospective 1-hour IL-6/sTNFR1 plus bicarbonate panel operationalized bedside ARDS subphenotyping. A validated three-biomarker ML score (PCT, sTREM-1, IL-6) quantified immune dysregulation and identified hydrocortisone-responsive patients. Mechanistic studies nominated druggable host pathways—STA

Sepsis Research Analysis

February’s sepsis research converged on host-directed immunomodulation and pragmatic implementation. A large cluster RCT in Nature Medicine showed that a digitally enabled stewardship program markedly reduced antibiotics for respiratory infections without increasing sepsis-related hospitalizations. Mechanistic advances identified a BDNF-derived peptide (BDP-12) that antagonizes TLR4 to blunt lung inflammation and an FGF13–ERK/HIF-1α glycolytic axis that is therapeutically tractable. Neuroepigene

Sepsis Research Analysis

January’s sepsis research converged on host-centered mechanisms, precision adjuncts, and rapid diagnostics, with recency-weighted normalization highlighting late-month mechanistic breakthroughs. Platelet-derived PITT structures and neutrophil EGFR–PGLYRP1–TREM-1 signaling emerged as druggable thrombo-inflammatory axes. A Nature study reframed outcomes through disease tolerance and aging, while multi-omic risk enrichment (BEYOND) demonstrated a clinically meaningful adjunctive benefit in a random

Sepsis Research Analysis

December’s sepsis research converged on precision, with phenotype-guided immunotherapy (ImmunoSep, JAMA) improving early organ dysfunction and multi-omic/AI frameworks sharpening stratification. Mechanistic advances spotlighted endothelial injury and protection: a DLL4–Notch1 neutrophil–endothelium axis driving PANoptosis in septic lung injury, ferroptosis resistance via the Piezo1–BHLHE40–SLC7A11 pathway, and an immunothrombosis IFNβ–MALAT1–caspase-11 axis predicting early DIC. Cardiac protecti

Sepsis Research Analysis

November’s sepsis research converged on precision stratification and deployable diagnostics while preserving pragmatic implementation signals. A rapid time-resolved host transcriptomic signature predicted antibiotic response within 24 hours in neonatal sepsis, and explainable AI using routine labs (SMART/SepsisFormer) produced interpretable risk tiers and coagulation–inflammation subphenotypes that may guide anticoagulation. A goal-directed multi-omics framework linked biological heterogeneity t

Sepsis Research Analysis

October’s sepsis literature converged on precision biology, rapid diagnostics, and host-directed therapeutics. Two Nature Medicine frameworks (consensus blood transcriptomic subtypes and myeloid/lymphoid immune-compartment dysregulation) matured into actionable endotyping tools that link molecular states to treatment interactions and stratified trial design. At the bedside, a single-centre Lancet Microbe study operationalized same-day, pan-kingdom metagenomics with measurable changes in antimicr

Sepsis Research Analysis

September’s sepsis research converged on mechanistic, druggable targets and immunometabolic control. Two high-impact studies mapped cardiometabolic protection via MacroD1-mediated mitochondrial regulation and an anti-inflammatory metabolite, homocysitaconate, that reprograms methionine metabolism through MARS inhibition. A complementary kinase-focused study identified Src as an upstream regulator of NETosis and acute organ injury with human correlative data. Diagnostics and prognostics advanced

Sepsis Research Analysis

August sepsis research coalesced around immunometabolic mechanisms driving organ dysfunction, precision antimicrobial dosing during renal replacement therapy, and biomarker-guided immunomodulation. A mechanistic cascade from phospholipid signaling to HIF-1α–mediated cytopathic hypoxia clarified targets for septic cardiomyopathy, while the IDO1–Kyn–AhR–ferroptosis axis linked metabolism to thymic immune attrition. Clinically, externally validated nomograms optimized beta-lactam dosing in RRT, and

Sepsis Research Analysis

July’s sepsis literature coalesced around three themes: a systems-level glycoproteomic regulator tied to outcomes, critical gaps in bedside hemodynamic monitoring validation, and a mechanistically novel antimicrobial entry pathway with in vivo efficacy. Work on the mannose receptor Mrc1 linked lectin biology to broad shifts in circulating mannosylated proteins and sepsis mortality, reframing biomarker interpretation. A rigorous meta-analysis challenged reliance on many cardiac output monitors in

Sepsis Research Analysis

June 2025 sepsis research converged on precision immunology, actionable inflammatory circuits, and deployable diagnostics. A conserved 42-gene SoM signature linked baseline risk to infection severity and predicted steroid-related harm, while mechanistic studies exposed CK2–PGK1–NLRP3–USP14 inflammasome signaling and chromatin-based NFIL3 restraint. Organ-protection biology advanced with lactate-driven HADHA lactylation implicating SIRT1/3 in septic cardiomyopathy and a vagal brain–adrenal–lung c

Sepsis Research Analysis

May’s sepsis research converged on immunometabolic mechanisms, early biomarker discovery, pathogen genomics, and pragmatic ICU practice. Cross-species multi-omics highlighted serine-centered metabolic shifts and mitochondrial downregulation as early discriminators of sepsis. Mechanistic and preclinical studies identified druggable neuroimmune nodes (dopamine–DRD2–TLR4–ACOD1–PD-L1) and metabolic adjuncts (ketogenesis/acetoacetate) that sensitize bacteria to antibiotics. Pathogen genomics linked E

Sepsis Research Analysis

April’s sepsis research converged on precision phenotyping, stewardship, and mechanism‑driven therapeutics. A multicenter RCT showed that a 7‑day antibiotic course is non‑inferior to 14 days for selected neonatal sepsis, enabling shorter, safer regimens. A Cell proteome atlas linked plasma proteins to organ origins, advancing organ‑specific diagnostics, while a British Journal of Pharmacology study identified an ALOX12–Caspase‑11 lipid‑peroxidation checkpoint (GL‑V9) that reduced pyroptosis and

Sepsis Research Analysis

March 2025 sepsis research converged on endothelial biology, rapid diagnostics, and pragmatic implementation. A druggable endothelial ferroptosis checkpoint (EV‑mediated GBP2–OTUD5–GPX4) and an ANGPT2–cathepsin K Tie2-antagonist switch sharpened host-targeted therapy concepts, while an externally validated reinforcement-learning policy suggested earlier vasopressin could improve outcomes. Rapid diagnostic advances spanned time-series EHR AI for pre-culture BSI prediction and lab-side accelerator

Sepsis Research Analysis

January’s sepsis research converged on host-directed mechanisms and actionable bedside strategies. High-impact mechanistic work linked platelet immunothrombosis to a druggable metabolic node (IRAP) and connected a human prognostic biomarker (PLTP) to therapeutic rescue in animal SA-AKI models. Clinical evidence matured around resuscitation choices, including a pragmatic ED pilot of early concentrated albumin and a meta-analysis suggesting a 1–3 hour vasopressor initiation window in septic shock.